70 A phase II clinical trial has yielded promising results for a novel combination therapy for HR+/HER2+ metastatic breast cancer, a group of patients often resistant to standard treatments. Researchers from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, led the study, which demonstrated that combining pyrotinib, an irreversible tyrosine kinase inhibitor, with fulvestrant, a selective oestrogen receptor degrader, offers substantial clinical benefits. The findings, published in the journal National Science Review, suggest this therapy could become a crucial option for patients with advanced breast cancer, particularly those who have not responded well to trastuzumab-based therapies. The trial was conducted across five hospitals in China and included 46 patients with metastatic breast cancer who had previously experienced progression on trastuzumab, a first-line treatment. Patients were administered daily oral pyrotinib (400 mg) along with fulvestrant injections (500 mg, given as per the study protocol). The main goal of the study was to evaluate the efficacy and safety of this combination therapy in treating HR+/HER2+ metastatic breast cancer. The study’s primary outcome measure was progression-free survival (PFS), which refers to the length of time during and after treatment that a patient lives with the disease without it getting worse. The results showed that the median PFS for all participants was 18.2 months. Notably, patients who received this combination therapy as a first-line treatment had a longer PFS of 19.5 months. Even in patients with brain metastases – a subgroup notoriously difficult to treat – the PFS was an impressive 18.4 months. An outstanding 97.5% of patients in the trial exhibited disease control, meaning their cancer did not worsen during the study period. Of these patients, 32.5% experienced objective responses, including both complete and partial responses, highlighting the effectiveness of the combination therapy. The safety of the combined treatment was another key consideration in the trial. Overall, the therapy was well tolerated by patients, with no grade 4 or higher adverse events reported. The most common adverse event was grade 3 diarrhoea, which affected 26.1% of participants. This side effect was managed effectively with supportive care, indicating that the treatment is manageable for most patients. The study also explored the potential for precision medicine by investigating biomarkers that could predict a patient’s response to the treatment. The results showed that patients with low tumour mutation burden (TMB) and ZNF217 mutations had enhanced responsiveness to the therapy. This finding is particularly significant as it suggests that the treatment could be tailored to individual patients based on their genetic profiles, thus paving the way for more personalised cancer treatments in the future. This trial underscores the potential of combining pyrotinib and fulvestrant as a chemotherapy-free alternative for HR+/HER2+ metastatic breast cancer. This is especially significant for patients who have become resistant to trastuzumab or those with brain metastases, which are traditionally difficult to treat. Given the combination’s promising efficacy and safety data, it could become a first-line treatment option in clinical practice. Building on the success of this phase II trial, the research team plans to initiate a phase III randomised controlled trial to compare this combination regimen with standard first-line therapies. The new trial will also incorporate advanced technologies, including artificial intelligence, to optimise patient selection and monitor trial outcomes in real time. This approach aims to further refine the treatment and ensure that it is as effective as possible for patients who need it the most. The results from this study are a major step forward in the fight against metastatic breast cancer, offering hope for a new treatment approach that may significantly improve patient outcomes, particularly for those who have limited options due to resistance to existing therapies. As the research progresses, there is growing optimism that this novel combination therapy could become a cornerstone of treatment for HR+/HER2+ metastatic breast cancer. This breakthrough is a reminder of the ongoing advancements in cancer research and the importance of personalised medicine, where treatments are increasingly designed to fit the unique characteristics of each patient’s cancer. The results could signal a significant shift in how metastatic breast cancer is treated, offering new hope for patients worldwide.